Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Employees - 952, CEO - John Charles Jacobs, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -4.4, Piotroski Score(max is 10): 1, Working Capital: $508355000, Total Assets: $1043162000, Retained Earnings: $-4577639000, EBIT: -64460000, Total Liabilities: $1187924000, Revenue: $596338000

- Current Price $ - Analyst Target Price $